There are currently 78 active clinical trials seeking participants for Myelodysplastic Syndromes research studies. The states with the highest number of trials for Myelodysplastic Syndromes participants are Ohio, California, New York and Texas.
Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood
NCT06904482
Recruiting
The purpose of this study is to see if see if adding the specific combination of donors can result in acceptable levels of survival without evidence of disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/15/2025
Locations: Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland, Ohio
Conditions: aGVHD, Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndromes
Register for Updates
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations
NCT06630221
Recruiting
The purpose of this study is to evaluate if a study drug called eltrombopag can improve the blood cell counts in patients with low-risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) with mutations in TET2 gene, observe changes in the TET2 gene over time, and evaluate the effectiveness of the treatment. TET2 gene is one of the most frequently mutated genes (altered parts of the DNA) in MDS and CMML. Eltrombopag is a Food and Drug Administration (FDA) approved drug fo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland, Ohio
Conditions: Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
Register for Updates
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
NCT06847867
Recruiting
The goal of this clinical trial is to determine if momelotinib is safe and effective for people with low-risk myelodysplastic syndromes (LR-MDS). The trial will also examine how the body processes the drug. The study is comprised of two parts: Part 1: Participants will receive different doses of momelotinib to find the best dose by evaluating effectiveness in improving red blood cell transfusion requirements and safety. Part 2: Participants will receive dose selected from Part 1 to assess its im... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: GSK Investigational Site, Canton, Ohio
Conditions: Myelodysplastic Syndromes
Register for Updates
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
NCT06680661
Recruiting
The goal of this clinical trial is to see if adding abatacept to tacrolimus and MMF prevents or reduces the chances of acute graft versus host disease which is a complication that can occur after transplant in participants with blood cancer. The usual therapy for graft versus host disease prevention after a cord blood transplant includes tacrolimus and MMF. The main question this clinical trial aims to answer is whether or not abatacept will be safe and effective in reducing aGVHD rates in dCBT.... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/02/2025
Locations: University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Acute Myelogenous Leukemia, Acute Lymphatic Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndromes, Myelodysplastic Syndrome Other, Chronic Myelomonocytic Leukemia, Lymphoma, Hodgkin Lymphoma
Register for Updates
Natural Killer (NK) Cells in Combination with Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
NCT05400122
Recruiting
One of the ways that cancer grows and spreads is by avoiding the immune system.NK cells are immune cells that kill cancer cells, but are often malfunctioning in people with colorectal cancer and blood cancers. A safe way to give people with colorectal cancer and blood cancers fresh NK cells from a healthy donor has recently been discovered. The purpose of this study is to show that using two medicines (vactosertib and IL-2) with NK cells will be safe and will activate the donor NK cells. NK cell... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Colorectal Cancer, Hematologic Malignancy, Rectum Cancer, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Hodgkin Lymphoma, Non Hodgkin Lymphoma, Myeloproliferative Syndrome, Plasma Cell Myeloma, Gastric Cancer, Esophageal Cancer, Esophagus Cancer, Gastric Cancer, Metastatic, Unresectable Esophageal Cancer, Metastatic Esophageal Cancer
Register for Updates
5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies
NCT04187703
Recruiting
Another term for myelodysplastic syndrome is bone marrow failure. The bone marrow is where components of blood such as red cells, platelets and white cells are made. In bone marrow failure, the ability for bone marrow to make these cells is decreased. In myelodysplastic syndrome, this decreased bone marrow function is believed to result from abnormalities that prevent the normal maturation process by which bone marrow cells develop into red blood cells, white blood cells and platelets. In myelod... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/05/2024
Locations: Cleveland Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Myelodysplastic Syndromes, MDS/MPN Crossover Syndromes
Register for Updates
A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
NCT06566742
Recruiting
To learn if olutasidenib can help to control CCUS, MDS, and/or CMML. The safety of the drug will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/20/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Clonal Cytopenia of Undetermined Significance
Register for Updates
A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)
NCT05490446
Recruiting
This purpose of this study is to establish proof of concept of tebapivat in participants with LR-MDS in Phase 2a and to evaluate the effect of tebapivat on transfusion independence (TI) in participants with LR-MDS in phase 2b.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: Innovative Clinical Research Institute Whittier, Lakewood, California +44 locations
Conditions: Myelodysplastic Syndromes
Register for Updates
ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
NCT05949684
Recruiting
The purpose of the study is to compare the efficacy and safety of Luspatercept vs epoetin alfa in the treatment of anemia in adults due to IPSS-R very low, low, intermediate-risk MDS in ESA-naïve participants who are non-transfusion dependent (NTD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: Community Cancer Institute, Clovis, California +168 locations
Conditions: Myelodysplastic Syndromes
Register for Updates
Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants
NCT07019155
Recruiting
Background: Hereditary hematopoietic malignancy (HHM) syndromes are a group of inherited disorders that raises the risk of blood cancers. Many people with HHMs have changes in a gene (DDX41) that makes it more likely that they will develop myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), or other cancers. This natural history study will explore the link between HHM syndromes and these diseases. Objective: To study the link between HHM and MDS/AML. Eligibility: People aged 1 mon... Read More
Gender:
ALL
Ages:
Between 1 month and 120 years
Trial Updated:
08/13/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Germline Mutation, Myelodysplastic Syndromes, Acute Myeloid Leukemia
Register for Updates
Collection of Blood, Bone Marrow, Skin, Saliva, and Stool Samples From Healthy Volunteers Used for Comparative Analysis of Myeloid Malignancies
NCT05588154
Recruiting
Background: Myelodysplastic syndromes (MDS) are disorders of blood stem cells that can develop into blood cancers. Treatment options are limited. To find better treatments, researchers need to better understand how MDS develops. To do that, they must be able to compare biospecimens from people with the disease to those of healthy people. Objective: This study will create a database of biospecimens collected from healthy volunteers. Eligibility: Healthy people aged 18 and older. Design: Pa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Myelodysplastic Syndromes
Register for Updates
Home Blood Transfusions
NCT07121140
Recruiting
This is a pilot single arm study to evaluate the feasibility and acceptability of a home blood transfusion program. Patients will be enrolled with hematologic malignancies and other bone marrow failure syndromes who are transfusion dependent and interested in a home blood transfusion program. Participants enrolled in the study will receive 1-5 units of blood products at home. Data on barriers to administration will be recorded. Surveys and qualitative interviews will be completed to better under... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
Conditions: Hematologic Malignancy, Myelodysplastic Syndromes, Acute Myeloid Leukemia, Transfusion Dependent Cytopenias
Register for Updates